Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Presatovir in RSV-positive lung transplant recipients
NCT02534350Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of presatovir in respiratory syncytial virus infection (RSV), sponsored by Gilead Sciences. Started Dec 2015; status: completed.
02
Drugs
presatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02534350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534350.